| Description | KRN5 is an effective inhibitor of NFAT5 with an IC50 of 750 nM and can be used in studies about chronic arthritis. |
| In vitro | KRN5（1 μM）在LPS[1]刺激的RAW264.7巨噬细胞中，抑制NFAT5、IL-6、MCP-1和GM-CSF的表达。 |
| In vivo | 在用牛型II胶原蛋白免疫的DBA/1J小鼠中，KRN5（口服剂量分别为15和60 mg/kg）呈剂量依赖性地减轻关节炎的严重程度。KRN5显著降低小鼠血清中抗型II胶原蛋白IgG的浓度。此外，KRN5通过减少由脂多糖（LPS）刺激的小鼠脾细胞产生的TNF-α和IL-6水平[1]。 |
| Target activity | NFAT5:750 nM |
| molecular weight | 459.47 |
| Molecular formula | C27H22FNO5 |
| CAS | 1800465-47-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 5 mg/mL (10.9 mM), Sonication and heating to 80℃ are recommended. |
| References | 1. Han EJ, et al. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine. 2017 Apr;18:261-273. |